ESR1 and breast carcinoma: In order to extend the therapeutic effectivity of OBHS–HDAC conjugates above for both ER(+) and ER(−) breast cancer cells, Li et al. [136] reported a new family of ferrocene complexes (termed FcOBHS–HDACi conjugate) based on the OBHS–HDAC core scaffold (10c).